长江商报消息 ●长江商报记者 汪静 通策医疗（600763.SH）董监高出手回购。 2月24日晚间，通策医疗发布公告称，公司董事长王毅、董事黄浴华、董秘张华、财务总监徐国喜及其 他管理人员赵敏计划自2026年2月13日起6个月内增持公司股份。 根据公告，本次增持主体包括董事、总经理等高管人员，拟通过上海证券交易所系统以集中竞价方式实 施。增持金额合计不低于600万元，不超过1200万元，其中王毅、黄浴华、张华每人拟增持150万至300 万元，徐国喜拟增持50万至100万元，赵敏拟增持100万至200万元。资金来源为自有或自筹资金。 截至2月13日，上述人员已首次合计增持3.82万股，总金额约181.61万元。 长江商报记者注意到，随着千亿市值光环褪去，公司股价持续下滑，2024年4月一度跌至35.54元/股， 此后公司股价缓慢恢复增长，截至2026年2月24日，收报50.03元/股。 在2026年新年致辞中，通策医疗董事长王毅提出，"实现公司整体业绩同比增长30%"。通策医疗在此前 的调研会上表示，公司持续推进"大部制"改革，对2026年恢复稳步增长充满信心，并已正式重新提出内 部收入倍增计划。 董事和高管拟 ...

Core Viewpoint - The company reported steady growth in its financial performance for the first three quarters of 2025, with revenue and net profit showing positive year-on-year changes, indicating resilience in a cautious consumer environment [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.29 billion yuan (+2.56%) and a net profit attributable to shareholders of 514 million yuan (+3.16%) [1]. - In Q3 2025, the company recorded revenue of 842 million yuan (+2.34%) and a net profit of 192 million yuan (+2.15%) [1][2]. - The gross margin for the first three quarters was 41.7%, remaining stable compared to 41.8% in the same period last year [3]. Business Segmentation - The revenue structure for the first three quarters was balanced, with orthodontics and comprehensive services accounting for over half of total revenue [2]. - Orthodontics generated revenue of 426 million yuan, with Q3 revenue of 197 million yuan, representing 25% of Q3 revenue [2]. - Comprehensive services contributed 604 million yuan, with Q3 revenue of 210 million yuan, accounting for 27% of Q3 revenue [2]. Growth Drivers - The recovery in the orthodontics business is driven by two main factors: the implementation of centralized procurement policies stabilizing market expectations and the significant growth in early orthodontic treatments for children [2]. - The number of orthodontic cases in Q3 increased by 10.6%, indicating a recovery trend [2]. Cash Flow and Profitability - The company maintained a low sales expense ratio of 1.17%, reflecting strong brand power and customer acquisition capabilities [3]. - The net cash flow from operating activities for the first three quarters was 682 million yuan (+5.34%), with a cash flow to net profit ratio of 1.11, indicating ample cash flow [3]. Strategic Focus - The company is shifting its core drive from external expansion to enhancing internal efficiency, implementing a "big department system" reform to break down barriers in doctor resources [3]. - Digitalization efforts are aimed at improving productivity among over 1,600 existing doctors [3]. Investment Outlook - The company is actively implementing strategic plans to strengthen talent reserves and expand new hospitals and branches [4]. - Projected net profits for 2025-2027 are estimated at 512 million, 571 million, and 617 million yuan, with year-on-year growth rates of 2.2%, 11.5%, and 8.0% respectively [4]. - A target price of 51.10 yuan is set based on a 40x PE ratio for 2026, maintaining a "recommended" rating [4].